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Abstract
Background: Proximal femoral fractures are strongly associated with morbidity and mortality in elderly patients.
Mortality is highest among frail institutionalized elderly with both physical and cognitive comorbidities who
consequently have a limited life expectancy. Evidence based guidelines on whether or not to operate on these
patients in the case of a proximal femoral fracture are lacking. Practice variation occurs, and it remains unknown if
nonoperative treatment would result in at least the same quality of life as operative treatment. This study aims to
determine the effect of nonoperative management versus operative management of proximal femoral fractures in a
selected group of frail institutionalized elderly on the quality of life, level of pain, rate of complications, time to death,
satisfaction of the patient (or proxy) and the caregiver with the management strategy, and health care consumption.
Methods: This is a multicenter, observational cohort study. Frail institutionalized elderly (70 years or older with a body
mass index < 18.5, a Functional Ambulation Category of 2 or lower pre-trauma, or an American Society of
Anesthesiologists score of 4 or 5), who sustained a proximal femoral fracture are eligible to participate. Patients with a
pathological or periprosthetic fractures and known metastatic oncological disease will be excluded. Treatment decision
will be reached following a structured shared decision process. The primary outcome is quality of life (Euro-QoL; EQ-
5D-5 L). Secondary outcome measures are quality of life measured with the QUALIDEM, pain level (PACSLAC), pain
medication use, treatment satisfaction of patient (or proxy) and caregivers, quality of dying (QODD), time to death, and
direct medical costs. A cost-utility and cost-effectiveness analysis will be done, using the EQ-5D utility score and
QUALIDEM score, respectively. Non-inferiority of nonoperative treatment is assumed with a limit of 0.15 on the EQ-5D
score. Data will be acquired at 7, 14, and 30 days and at 3 and 6 months after trauma.
Discussion: The results of this study will provide insight into the true value of nonoperative treatment of proximal
femoral fractures in frail elderly with a limited life expectancy. The results may be used for updating (inter)national
treatment guidelines.
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Background
Proximal femoral fractures are amongst the most com-
mon fractures in the elderly [1] with the incidence rate
increasing with age. In the Netherlands 20,000 patients
are admitted with a proximal femoral fracture to the
hospital each year [2, 3]. This number is expected to rise
because of our ageing society. Approximately 20% live in
a nursing home prior to the fracture. Proximal femoral
fractures result in activities of daily living (ADL) depend-
ence and increased morbidity, strongly diminishes the
patients’ (health-related) Quality of Life (QoL) and total
health care costs [4–7].
A proximal femoral fracture is also strongly associated
with mortality. Over 30% of patients die within the first
year and 8–13.3% die within the first month [8–10].
Mortality is highest among elderly with both physical
and cognitive comorbidities [9, 10]. A 36 and 55% mor-
tality rate within 6 months after fracture has been re-
ported for institutionalized patients and patients with
advanced dementia, respectively [11, 12]. This shows
that the hip fracture is merely a symptom of the frail sta-
tus of these patients and the start of cascade breakdown
at the end of life.
Operative treatment allows early mobilization, is ef-
fective in pain relief, and is believed to prevent second-
ary complications like pneumonia, urinary tract
infection, and pressure sores. However, surgery will not
prevent frail patients from developing aforementioned
complications. Instead, patients may develop additional
surgical complications like bleeding, infection, and non-
union, necessitating further (operative) interventions
[13]. Hospital admission after a proximal femoral frac-
ture itself can provoke cognitive impairment or delirium
in these patients who often live in delicate equipoise in
an institutionalized setting.
Although surgery is considered a good analgesic op-
tion, it is not the only analgesic option. Moreover, sur-
gery also has disadvantages. It is questionable whether
surgery is beneficial in terms of quality of life and
whether surgery is satisfactory for family and caretakers
involved. The World Health Organization (WHO) defin-
ition for palliative care supports a holistic approach in
facing life-threatening illness, which is a proximal fem-
oral fracture in a frail elderly patient. Randomized trials
comparing operative and nonoperative management in
institutionalized elderly are scarce, due to ethical issues,
and focus on mortality instead of quality of life.
Guidelines have no strict advice for frail elderly with a
proximal femoral fracture, as a result of lack of evidence
on palliative care in these patients. The National Insti-
tute for Health and Care Excellence (NICE) advises to
discuss if patients are open to hospital admission and
possible surgery [14]. Dutch guidelines advocate opera-
tive treatment in patients with a life expectancy beyond
6 weeks [2, 15]. This leads to practice variation. Current
practice is that over 90% of femoral fracture patients that
presented to hospital are operated, even if they are insti-
tutionalized and have a limited life expectancy [16].
A systematic review of the literature on nonoperative
management versus operative management of proximal
femoral fractures in frail elderly resulted in 7 studies that
met the eligibility criteria [17–24]; All were nonrando-
mized, five were retrospective studies. A total of 1189
patients were included, 242 (20.3%) were treated nono-
peratively. The mean age ranged from 76.9–101.8 years.
The data indicated an unadjusted pooled odds ratio of
3.95-fold and 3.84-fold higher 30-day and 1-year mortal-
ity for nonoperative versus operative management. Data
also showed that mortality was affected by the number
of comorbidities. None of the comparative studies exam-
ined (health-related) quality of life, degree of frailty, and
costs. The literature review shows a lack of high quality
evidence on the true effect of nonoperative versus opera-
tive management on quality of life, pain, mortality, com-
plications, and costs in the first 6 months after trauma
in frail institutionalized elderly. Those answers are
needed to aid patients and health care providers in
decision-making for surgical repair, particularly in frail
elderly patients. The above shows that the best treat-
ment is not known, and supports the need for high qual-
ity evidence. Evidence supporting (non)operative
management in terms of quality of life, pain, complica-
tions, and mortality is lacking.
It is common practice to decide on treatment follow-
ing a shared decision process, but still nonoperative
treatment is uncommonly used. It is unclear to what ex-
tent patients or their relatives currently have a say in the
treatment decision.
This study aims to investigate the effect of nonopera-
tive management versus operative management of prox-
imal femoral fractures in a selected group of frail
institutionalized elderly with regards to quality of life
and clinical outcomes. Treatment decision will be
reached following a structured shared decision process,
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in which pros and cons of both operative and nonopera-
tive management are discussed with patients, their rela-
tives, and all relevant care providers involved.
Methods/design
Aim of the study
This study aims to investigate the effect of nonoperative
management versus operative management of proximal
femoral fractures in a selected group of frail institution-
alized elderly on the quality of life, level of pain, rate of
complications, time to death, satisfaction of the patient
(or proxy) and the caregiver with the management strat-
egy, and health care consumption.
Study design and setting
This study will be a two-arm non-randomized (observa-
tional) multicenter cohort study and an economic evalu-
ation alongside. The study will be conducted with a non-
inferior design. Relevant societies for surgery (Dutch As-
sociation of Surgery (NVvH), Dutch Association of
Trauma Surgery (NVT), Dutch Orthopaedic Association
(NOV), and Dutch Association of Orthopaedic Surgery
(NVOT)), clinical geriatrics (Dutch Association of Clinical
Geriatrics (NVKG)), elderly care (Association of Elderly
Care Physicians (VERENSO)), the Dutch Patient Feder-
ation, and two committee members of the Dutch guideline
for treatment of proximal femoral fractures are repre-
sented in the study team. Patients will be recruited from
several hospitals throughout The Netherlands. The follow-
ing 26 hospitals will participate: Albert Schweitzer Zieken-
huis, Alrijne Ziekenhuis, Amphia Ziekenhuis, Amsterdam
UMC (location VUmc), Bernhoven, Catharina Ziekenhuis,
Deventer Ziekenhuis, Dijklander Ziekenhuis (location
Westfriesgasthuis), Dijklander Ziekenhuis (location
Waterland Ziekenhuis), Elisabeth TweeSteden Ziekenhuis,
Erasmus MC, Flevo Ziekenhuis, Isala, Maasstad Zieken-
huis, Meander MC, Noordwest Ziekenhuisgroep, OLVG,
Radboud UMC, Rijnstate, Rode Kruis Ziekenhuis, St. An-
tonius Ziekenhuis, Streekziekenhuis Koningin Beatrix,
Tergooi, Ziekenhuis Gelderse Vallei, Ziekenhuis Tjon-
gerschans, and Zorggroep Twente.
The study has started in September 2018. The recruit-
ment period will be 24 months, with a follow-up of 6
months. The results of the study are expected mid-2021.
Study registration
The study is registered at the Netherlands Trial Register
(NTR7245; date 10-06-2018).
Study population and eligibility criteria
This study focuses on frail institutionalized elderly who
have a limited life expectancy and fracture their prox-
imal femur. In order to be eligible to participate in this
study, a subject must meet all of the following criteria:
1) Frail institutionalized elderly person (i.e., 70 years or
older, living in a nursing home pretrauma, who
either:
a) is malnutritioned (i.e., cachexia or a Body Mass
Index, BMI, of < 18.5 kg/m2); or
b) has mobility issues with increased risk of falling
pretrauma (i.e., Functional Ambulation Category
(FAC) 2 or less) *; or
c) has severe comorbidities (American Society of
Anesthesiologists (ASA) class 4 or 5).
2) Acute proximal femoral fracture, confirmed on X-
ray or CT-scan
3) Provision of informed consent by patient or proxy
* The FAC is a functional walking test that evaluates
ambulation ability [25, 26]. This 6-point scale assesses
ambulation status by determining how much human
support the patient requires when walking, regardless of
whether or not they use a personal assistive device. FAC
category 2 are patients who require manual contact of
no more than one person during ambulation on level
surfaces to prevent falling, consisting of continuous or
intermittent light touch to assist balance or coordin-
ation. Patients categorized as 0 (nonfunctional ambula-
tory), 1 (dependent for continuous and necessary
physical assistance) to 2 due to a temporary and easily
resolvable problem will not be eligible.
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
1) Bilateral proximal femoral fractures
2) Periprosthetic fracture
3) Fracture diagnosed more than 7 days after trauma
4) Patients with a known metastatic disease and a
confirmed pathological fracture of the proximal
femur
5) Insufficient comprehension of Dutch language to
understand rehabilitation programs and other
treatment information (this applies to the person
signing consent, being either the patient or proxy)
6) Participation in another surgical intervention or
drug study that might influence any of the outcome
parameters
Treatment of participants
Shared decision process
The decision for type of treatment (operative or nonop-
erative) is achieved by shared decision making (SDM).
Shared decision making is based on determining the
goals of care for the patient [27]. The purpose of goals
of care is to safeguard patients who are unlikely to bene-
fit from operative treatment, especially in patients in the
palliative or terminal phase. Goals of care discussion
with these frail elderly patients, or in case of cognitive
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impairment, with a proxy at the onset of proximal fem-
oral fracture are useful in shared decision making. Al-
though some form of SDM is also used in current
practice, this study will use a much more structured ap-
proach towards this process. Prior to start of treatment,
patients will be informed in an objective and structured
way about what either treatment arm of the study in-
volves and what complications may occur in either tre-
atment arm. Both for nonoperative and operative
management, a full forecast is given verbally and on
paper. Combined with the preferences and objections of
the patients or their proxy, this is the starting point of a
shared decision process. All principal health care pro-
viders (i.e., a trauma or orthopedic surgeon, elderly care
physician, and geriatrician if possible) as well as the pa-
tient and his/her relative(s) or legal representative will
take part in this shared decision process. The patients
perspective will play a key role in the decision process.
Nonoperative management group
The intervention group will be subjected to nonopera-
tive management of the proximal femoral fracture. This
group is referred to as nonoperative group. The aim is
to transfer patients back to their nursing home location
as soon as reasonably possible after treatment decision
has been made. Treatment is focused on patient comfort
and consists of pain control (often using opioids), with
breathing support and physical therapy and occupational
therapy consultation (for optimal lying and sitting pos-
ition) as deemed necessary by the multidisciplinary treat-
ment team. Anti-decubitus mattresses beds and other
measures to prevent or treat complications will be used
as needed. Progression of comorbidities will also be
monitored closely. The general strategy and outline for
treatment will be the same for all patients. However, as
treatment needs to be tailored to the individual patient’s
needs, standardization of treatment is not possible. Rele-
vant details of treatment will be registered for possible
use in the statistical analysis.
Operative management group
Patient opting for operative treatment, will have opera-
tive management of the proximal femoral fracture (if
no medical contra-indications or objections by treating
physician). The choice of implant will depend on the
fracture type, and will adhere to the Dutch guideline
for hip fracture treatment [2]. In general, intracapsular
femoral neck fractures will be fixed with a (hemi)ar-
throplasty or screw fixation, and extracapsular pertro-
chanteric fractures with a dynamic hip screw, dynamic
compression screw, or an intra-medullary fixation. Peri-
operative care will be according to local hospital proto-
cols in order to have a real-life situation. As soon as
reasonably possible after surgery, patients will return to
their nursing home for further (palliative) care. The
principles for palliative care are the same as described
for the nonoperative group. Relevant details of treat-
ment will be registered for possible use in the statistical
analysis.
Outcome measures and data collection
The primary outcome measure is the quality of life as
reported by the patient or proxy. The EuroQoL-5D
(EQ-5D) is a standardized instrument for use as a
measure of health outcome. It is among the most com-
monly used instruments for femoral fracture patients
[28, 29]. EQ-5D use is recommended for the assess-
ment of quality of life in trauma patients, especially for
economic assessments [30, 31]. The EQ-5D-5 L descrip-
tive system consists of five dimensions of health (mobil-
ity, self-care, usual activities, pain/discomfort anxiety/
depression), each with five possible answers. It is avail-
able in a self-report and a proxy version. The patients’
EQ-5D-5 L health status will be converted into utility
scores using the Dutch tariff [32]. Utility scores rang
from zero to one, with lower scores indicating poorer
quality of life.
The following secondary outcome measures will be
used:
1) Quality of life, measured with the QUALIDEM;
QUALIDEM (DL010) measures quality of life in
persons with dementia (regardless of severity) who
live in a nursing home or elderly care facility [33].
The instrument has been developed by the Trimbos
Institute and VUmc/EMGO-institute, department of
Psychiatry and department of Social and Elderly Care
[34]. The QUALIDEM consists of 37 items about the
last 7 days rated on a four-point Likert scale. Items
are divided into nine subscales (i.e., care relationship,
positive affect, negative affect, restless tense behavior,
positive self-image, social relations, social isolation,
feeling at home, and having something to do). Care-
givers complete the questionnaire, which has accept-
able psychometric properties [33, 35].
2) Level of pain and analgesic drug use: The level of
pain will be determined using the Pain Assessment
Checklist for Seniors with Limited Ability to
Communicate (PACSLAC), which was designed to
be a clinically useful scale for assessing pain in
patients with dementia [36]. This instrument has
been shown to be among the instruments with the
strongest psychometric properties for measuring
pain and lack of comfort in elderly in a long-term
care setting [37]. The instrument is a 24-item
questionnaire covering three sub-scales (facial and
vocal expression, resistance/defense and social-
emotional aspects/mood of the patient). A validated
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Dutch version (PACSLAC-D) is available [38, 39].
Trained caregivers can use the instrument for
scoring the presence of pain. The total score is a
summation of the 24 items that are each scored as
present (1 point) or absent (0 points). The total
score thus ranges from 0 to 24. A score of 4 points
or higher indicates pain. In addition to the level of
pain we will also register the amount of analgesic
medications used. All analgesic medication given
will be registered from the patients’ medical files.
Opioids will be combined. Opioid use will be
defined as daily oral morphine need. Daily narcotic
use will be calculated using the equivalence scale
for 30 mg/day oral morphine. Calculation of the
equivalent morphine dosage allows for comparison
between the two treatment groups.
3) Time to death: Mortality including (presumed)
cause of death will be registered. This will be
expressed as mean (or median, as applicable) time
to death as well as the rate of mortality within 1
week, 30 days, 3 months, and 6 months.
4) (Surgical) complications: This will include general
complications that may occur in both groups (e.g.,
urinary tract infection, pneumonia, pressure sores,
delirium, and comorbidity related complications like
cardiac arrhythmia, aspiration during intubation,
CVA) as well as early post-operative complications
(e.g., hematoma, bleeding, blood loss, wound
leakage, superficial infection, epidural bleeding due
to spinal anesthesia) and late post-operative
complications (e.g., deep infection, dislocation, or
implant failure, blood loss requiring transfusion <
48 h after surgery). Complications will be
categorized for level of severity and treatment
necessity according to the Clavien-Dindo
classification [40].
5) Satisfaction of the patient (or proxy) with the
chosen treatment: At the last study visit, the
patient (or proxy, as applicable) as well as the
patient’s caregiver will be asked to complete an
11-point Numeric Rating Score asking about
their satisfaction with the chosen treatment.
Herein, 0 = extremely dissatisfied and 10 =
extremely satisfied. For patients who have died,
their relatives and caregiver will be asked to
complete this Numeric Rating Scale. Patients
relatives will also be asked to participate in an
interview about the Quality of Dying and
Death (QODD). This is a 17-item interview-
based questionnaire asking about 17 end-of-life
priorities. Each item includes a filter question
reporting what actually occurred during the final
period of the decedent’s life (and how often),
followed by a rating of what occurred (using a
scale ranging from 0 (‘terrible experience’) to 10
(‘almost perfect experience’) [41, 42].
6) Satisfaction of the patient’s caregiver with the
chosen treatment (11-point Numeric Rating Score,
ranging from zero (extremely dissatisfied) to 10
(extremely satisfied).
7) Health care resource utilization (with associated
costs); relevant data will be collected using a
questionnaire that is based on the validated Medical
Consumption Questionnaire (iMCQ; institute of
Medical Technology Assessments iMTA, Erasmus
University, Rotterdam. NL) iMCQ details medical
specialist care, physical therapy, hospitalization,
nursing home, medication use, and other costs
directly associated with diagnosis, treatment, and
rehabilitation. Health care use and associated costs
until 6 months after trauma will be measured in
accordance with economic guidelines [43]. Cost
prices of the standardized referral strategy will be
determined by bottom-up micro-costing method.
The incremental cost-utility ratio of nonoperative
management versus operative management will be
expressed as costs per Quality Adjusted Life Years
(QALY) (EQ-5D utility score) gained, with
confidence ellipses and acceptability curves. A cost-
effectiveness analysis, with QUALIDEM score as
outcome measure, will also be done.
Other study parameters
In order to assess whether the treatment groups are
similar with respect to baseline characteristics, several
patient characteristics, injury characteristics, details of
the shared decision process, and treatment characteris-
tics will be collected.
Patient characteristics
– Age
– Gender
– BMI
– ASA grade
– Tobacco consumption at baseline
– Charlson Comorbidity Index (CCI) [44]
– Medication use prior to trauma
– FAC score
– Katz Index of Independence in Activities of Daily
Living (KATZ-ADL score)
Injury characteristics
– Affected side
– Type of fracture
– Additional injuries
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Details of shared decision process
– Participants in process
– Treatment goals of each participating party
– Relevant details of shared decision process
Treatment characteristics
– Hospital admission
– Surgical delay
– Name of surgeon
– Primary and secondary surgeon (resident or staff
surgeon)
– Duration of surgery
– Type of anesthesia
– Peripheral nerve block
– Details of nonoperative treatment
– Type of implant used
– Peroperative complications
– Mobilization orders
– Anti-decubitus mattress
Recruitment and informed consent
Eligible persons presented to the Emergency Department
(ED) with a proven proximal femoral fracture will be in-
formed about the study in the ED or upon admission at
the surgical or geriatric ward. After an explanation of
the study, they will receive written information and a
consent form from the attending physician, the clinical
investigator, or a research assistant. Patients meeting all
inclusion criteria and none of the exclusion criteria will
be recruited in the hospital within 48 h after hospital ad-
mission. Should patients not be able to sign informed
consent themselves, a legal representative (proxy) will
receive verbal and written information about the study
by the attending physician, the clinical investigator, or a
research assistant, and will be asked to consent with par-
ticipation of the patient. After signing informed consent
by patient or proxy, the shared decision process will be
carried out using a structured approach. This will result
in identifying the primary treatment that is deemed best
for the individual patient. Participation in this study is
on a voluntary basis. If patients (or proxy on their be-
half) do not wish to participate, they can do so without
specifying why. Deciding not to participate in the study
will not affect regular treatment and follow-up care. Par-
ticipants are allowed to withdraw from the study at any
time after they have given their written consent.
Study procedures and follow-up
Patients will be followed until 6 months after trauma or
until death, whichever comes first. In addition, at the 6-
month follow-up contact, the researcher or research as-
sistant will document any secondary intervention that
may be planned for the patient. A schedule of events is
shown in Table 1. A flow chart is shown in Fig. 1.
Following enrolment, treatment (either nonoperative
or operative management) will be decided using a shared
decision approach as mentioned above. Data will be ac-
quired at 7, 14, and 30 days, and at 3 and 6 months after
trauma.
Baseline data will be collected from the patient’s med-
ical files or by interviewing the patient as soon as pos-
sible, but no later than at the visit after enrolment. At
each follow-up visit, the coordinating researcher or
research assistant will visit the patient. He will ascertain
patient status (i.e., treatment details including analgesics
and other health care use, mobility of the patients,
adverse events/complications, secondary interventions,
and will verify information within medical records). At
each visit patients (or proxy) will be asked to complete a
questionnaire for the EQ-5D. At those visits, a caregiver
will be asked to complete the QUALIDEM and
PACSLAC-D.
At the final visit at 6 months, patients (or proxy) and
caregiver will be asked to complete a questionnaire relat-
ing to their satisfaction with the treatment approach. In
case a patient has died during follow-up, his/her relatives
and caregiver will be asked to complete this question-
naire. In addition, relatives will be invited for an inter-
view to complete the QODD questionnaire. An early
withdrawal form will be completed if patients (or proxy)
decide to withdraw from the study.
Blinding
As with many surgical studies, patients and surgeons
cannot be blinded for the intervention. In order to re-
duce bias as much as possible, outcome assessment will
be performed using a standardized protocol. Outcome
measures include both objective and subjective items.
Statistical analysis
Data will be analyzed using the Statistical Package for
the Social Sciences (SPSS) version 24.0 or higher (SPSS,
Chicago, Ill., USA) and will be reported following the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) guidelines. Normality of con-
tinuous data will be tested with the Shapiro-Wilk test.
Homogeneity of variances will be tested using the
Levene’s test. A two-sided p-value < 0.05 will be taken as
threshold of statistical significance in all statistical tests.
The analysis will be performed on a per-protocol basis,
(as that is the most conservative approach) and verified
by an intention-to-treat analysis if needed. Patients who
have died will remain in the analysis as censored. If ne-
cessary, missing values will be replaced using multiple
imputation following the predictive mean matching
method, using ten imputations.
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Descriptive analysis will be performed in order to re-
port the outcome measures and other variables collected
for the entire population as well as per treatment group.
Continuous data will be reported as mean and SD (if
Normal) or median and quartiles (if non-Normal), cat-
egorical data as number with percentage.
Univariate comparison between the groups will be
done using Student’s T or Mann-Whitney U-test (for
Normal and non-Normal data, respectively), or Chi-
squared test or Fisher’s Exact test (categorical data, as
applicable). The Student’s T-test will be done with equal
variance assumed or not assumed, based upon the re-
sults of the Levene’s test.
For the primary outcome measure, a non-inferiority
margin of 0.15 points for mean EQ-5D scores was
chosen because it is reasonable and on the border of
what would be considered a clinically important effect.
The null hypothesis in the non-inferiority framework is
that nonoperative management is inferior to operative
management with regards to the EQ-5D score. This
Table 1 Schedule of events and follow-up
Radiographs & Event forms Screening Enrolment 7 days
(4–10 days)
14 days
(11–17 days)
30 days
(23–37 days)
3 months
(11–15 weeks)
6 months
(6–7 months)
X-ray or CT-scan X
Screening X
Informed Consent X
Shared Decision X
Baseline Data X
General Clinical FU X X X X X
QoL (EQ-5D and QUALIDEM) Xa X X X X
PACSLAC and Analgesic use Xa X X X X
Complications and mortality X X X X X
(Secondary) Interventions X X X X X
Satisfaction of patient (or proxy) Xb Xb Xb Xb X
QODD Xb Xb Xb Xb Xb
Satisfaction of caregiver Xb Xb Xb Xb X
Health Care Use Xa X X X X
Early Withdrawal c c c c c
EQ-5D is completed by proxy and (if possible) by patients themselves
aAsking for current and pre-trauma status; bOnly if patients died prior to that follow-up moment; cOnly if applicable
Fig. 1 Flow of participants through the study
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hypothesis will be tested through the adjusted contrast
between the two interventions at 6 months. Specifically,
the 95% confidence interval of the estimated contrast
will be examined, and if the limit of the interval is less
than the threshold value of 0.15 points, non-inferiority
of nonoperative management to operative management
at 6 months will be concluded.
Multivariable analysis for continuous outcome mea-
sures that are repeatedly measured over time will be
done using generalized estimating equations (GEE) for
longitudinal analysis on a per-protocol and intention-
to-treat basis to investigate the effect of treatment. In
the primary GEE model, the primary outcome vari-
able studied (quality of life on EQ-5D) will be
analyzed as a dependent variable, using treatment
(nonoperative versus operative) as between subjects
variable and time as within subjects variable. The
interaction term of group and time (group x time)
will be assessed, to evaluate whether the change over
time differed between groups. Analyses will be cor-
rected for baseline differences and all models will be
corrected for center of inclusion. Repeatedly measured
continuous secondary outcome variables will be ana-
lyzed using similar GEE models. Continuous outcome
measures only ones and dichotomous secondary out-
come measures will be analyzed using multivariable
linear regression models and logistic regression
models, respectively.
Subgroup analysis are planned for patients with an
intracapsular or extracapsular fracture.
The economic evaluations will be done from a soci-
etal perspective. Intervention costs and health care
utilization costs until 6 months after inclusion will be
measured in accordance with economic guidelines [45].
Cost prices of the standardized referral strategy will be
determined by bottom-up micro-costing method. The
economic evaluation will be performed in accordance
with the intention-to-treat principle. Missing data will
be imputed using multiple imputation by changed
equations [46]. The Incremental Cost-Effectiveness Ra-
tio (ICER) of nonoperative versus operative manage-
ment will be calculated by dividing the difference in
costs by difference in effects. A cost-utility analysis,
with QALY (based on the EQ-5D utility score) as out-
come measure, will be done as primary economic
analysis. As secondary analysis, a cost-effectiveness ana-
lysis, with QUALIDEM as outcome measure, will be
done. In order to account for the possible clustering of
data, analyses will be performed using linear multilevel
analyses [47]. Accounting for the possible clustering of
data (e.g., at the hospital level) is very important, as
most economic evaluations fail to do so, whereas ignoring
the possible clustering of data might lead to inaccurate
levels of uncertainty and inaccurate point estimates [47].
Bootstrapping techniques will be used in order to estimate
the uncertainty surrounding the cost-effectiveness esti-
mates. Uncertainty will be shown in cost-effectiveness
planes and cost-effectiveness acceptability curves, and sen-
sitivity analyses will be performed in order to test the ro-
bustness of the study results [48–50].
Sample size calculation
The sample size calculation is based on a non-
inferiority design, i.e., on the hypothesis that nonopera-
tive management is non-inferior to operative manage-
ment. As stated before the EQ-5D will serve as primary
outcome measure. We have used the results from earl-
ier studies on proximal femoral fracture treatment in
the elderly for the sample size calculation [51–53]. As-
suming a two-sided significance level (alpha) of 0.05
and a power of 80% with a standard deviation (s) of
0.30 on the EQ-5D utility score and a noninferiority
limit (d) of 0.15 (which equals 0.5 SD), a total of 50
subjects are needed in each treatment arm. Taking into
account a rate of 60% loss to follow-up and mortality
until 3 months, a total number of 160 participants has
to be recruited.
Data management and monitoring
Data will be encoded and stored in a pass-word pro-
tected database with restricted access to the researchers
only. Data will be entered once. Quality of the entered
data will be monitored by checking entry for a random
sample of patients prior to database locking.
Discussion
Treatment guidelines for proximal femoral fractures are
mainly focused on regaining function and independence
in activities of daily living. Other considerations may
apply to frail elderly with a limited life expectancy, for
whom comfort and pain are particularly relevant.
Whether or not operative treatment is needed in this
respect is undecided. This study aims to investigate the
value of nonoperative management versus operative
management of proximal femoral fractures in a selected
group of frail institutionalized elderly with a limited life
expectancy.
There are some limitations to this study. First, selec-
tion bias could be a factor in this study, since patient or
proxy opting for nonoperative management may argu-
ably be in worse condition with regards to their pre-
trauma condition and comorbidities. A randomized
controlled trial (RCT) would have avoided selection
bias, however randomizing patients with a limited life
expectancy was considered unfeasible (and unethical)
by the research team. Patient recruitment in trials ran-
domizing between operative and nonoperative treat-
ment is known to be challenging, and would likely
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introduce an unacceptably high level of selection bias;
surgeons with clear preference for a particular treat-
ment may be unwilling to inform patients about the
study, and patients (or their proxy if patient is unable
to decide) with preference for a particular treatment
will not sign informed consent. The chosen observa-
tional design allows all centers and all patients to par-
ticipate, and real-life data will be collected. For patients
with severe cognitive impairment, informed consent
will be obtained by their health care proxy. That makes
the current study design the most feasible to investigate
this issue. As a second limitation, it could be argued
that the questionnaire completed by proxy may differ
from the patients rating, however since the majority of
this study population is expected to suffer from cogni-
tive impairment, questionnaire completion by proxy
will be inevitable. Finally, at least 26 hospitals will par-
ticipate, and treatment protocol and shared decision
processes may vary across sites. This may introduce
some heterogeneity, but also makes the results more
generalizable.
To the best of our knowledge, this is the first com-
parative study that addresses this issue with regard to
quality of life and cost-effectiveness and also the first
study to provide detailed information about nonopera-
tive management with a longer term follow-up in frail
patients with a proximal femoral fracture. This study will
contribute widely to the current knowledge about the
process of nonoperative management, treatment satisfac-
tion with patients, proxy and caregivers in this select
group of frail hip fracture patients in the context of
quality of life. The results of this study may be used for
updating the Dutch national “Guideline for the treat-
ment of proximal femoral fractures” (set out by the
Dutch Association of Surgery and the Dutch Ortho-
paedic Association) and the Dutch national “Guideline
for multidisciplinary treatment of vulnerable elderly
treated operatively” (set out by the Dutch Association of
Clinical Geriatrics), but may also help updating inter-
national treatment guidelines on proximal femoral frac-
tures. The results could be further used in the context of
advanced care planning and expectation management
and therefore aid treatment decision making in future
frail hip fracture patients.
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